Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
164M
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
36.3M
-
Shares change
-
-9.39M
-
Total reported value, excl. options
-
$52.6M
-
Value change
-
-$18.7M
-
Number of buys
-
30
-
Number of sells
-
-41
-
Price
-
$1.45
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q3 2022
96 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q3 2022.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.3M shares
of 164M outstanding shares and own 22.1% of the company stock.
Largest 10 shareholders include BVF INC/IL (6.6M shares), VANGUARD GROUP INC (4.54M shares), TANG CAPITAL MANAGEMENT LLC (3.5M shares), ACADIAN ASSET MANAGEMENT LLC (2.65M shares), Rubric Capital Management LP (2.41M shares), RENAISSANCE TECHNOLOGIES LLC (1.81M shares), BlackRock Inc. (1.8M shares), Laurion Capital Management LP (1.27M shares), PLATINUM INVESTMENT MANAGEMENT LTD (1.23M shares), and JACOBS LEVY EQUITY MANAGEMENT, INC (1.09M shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.